AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02910102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RVT-101 35 mg
Description: RVT-101 once daily, oral, 35-mg tablets
Study NCT02910102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo once daily, oral
Study NCT01005927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructooligosaccharide
Description: Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
Study NCT01005927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructooligosaccharide
Description: Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
Study NCT00997360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKI-179
Study NCT01179165 — intervention group
Intervention type: OTHER
Intervention: Diagnostic
Description: Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
Study NCT01802307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study NCT03496766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tipifarnib 600 mg will be administered until progression
Study NCT03570320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of opioid prescription method
Description: Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
Study NCT04591236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
Study NCT04591236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Description: Treadmill gait training was applied to Parkinson patients.
Study NCT04591236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: Treadmill gait training was applied to Parkinson patients.
Study NCT02048488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-011
Description: Number of cycles until progression or unacceptable toxicity develops.
Study NCT01436266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccally 2 hours prior to procedure
Study NCT01436266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: 2mg buccally 2 hours prior to procedure
Study NCT02134730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRIENDS for life
Description: Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
Study NCT03034902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined EEG and fNIRS
Description: The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
Study NCT04194125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
Study NCT02788058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Study NCT02788058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Study NCT02788058 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Hypofractionated Radiotherapy
Description: 40-45 Gy/5-15f
Study NCT01181674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: sc injection
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
Study NCT01181674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral administration
Study NCT01181674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: oral administration
Study NCT01181674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle therapy
Description: diet and exercise
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
Study NCT00673179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires to be completed on 5 different days during the study.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 1 hour, every other week.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
Study NCT00673179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
Study NCT00673179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
Study NCT01746979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TH-302
Description: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT01746979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT01746979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT01746979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (5 percent dextrose - D5W)
Description: TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT01492322 — intervention group
Intervention type: RADIATION
Intervention: TRODAT
Description: Smoker will receive a TRODAT injection
Study NCT02885961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dabigatran
Description: Anti-coagulant
Study NCT03840564 — intervention group
Intervention type: OTHER
Intervention: Point of care (POC)
Description: All the analyzes will be done in delocalized
Study NCT03420911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol
Study NCT03420911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02771470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Microbial composition using probiotic
Study NCT02771470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Microbiota modulation using placebo
Study NCT02234492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Comparison of rosuvastatin to no rosuvastatin
Study NCT02494661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Cart and Stress Management Videos
Description: Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
Study NCT02494661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Cart Video
Description: Healthy Cart Video: educational video on healthy food shopping
Study NCT03637426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
Study NCT03637426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite
Description: The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
Study NCT03637426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser + nano-hydroxyapatite
Description: GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
Study NCT03637426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
Study NCT02972892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Et Control Feature
Description: Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
Study NCT02972892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fresh Gas
Description: Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case.
Study NCT01907256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inverted V incision
Description: It is a type of incision
Study NCT01907256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stair step incisions
Description: It is a type of incision
Study NCT03650530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Family Talk Intervention
Description: The family meets two interventionists at six time points.
Study NCT00866944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adecatumumab
Description: Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
Study NCT00866944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adecatumumab and FOLFOX
Description: FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
Study NCT00866944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 4
Description: FOLFOX 4, every 14 days, 12 cycles
Study NCT02290444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone
Description: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
Study NCT04010552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALRINOX combination
Description: NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
Study NCT00817518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4987655
Description: Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
Study NCT00817518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4987655
Description: Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
Study NCT02274506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg by vein on Days -8 and -7.
Study NCT02274506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 by vein on Days -6 to -2.
Study NCT02274506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion
Description: T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
Study NCT03096158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilatory Muscle Training (TREMVEN)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
Study NCT01181674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard glycemic care
Description: as informed by the current clinical practice guidelines
Study NCT00666965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Study NCT00666965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Study NCT01364909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises
Study NCT01364909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual practice
Description: These patients will not receive exercise early in their intensive care admission
Study NCT01089075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: 20 mg po for 7 days (2 tablets)
Study NCT01089075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 tablets po
Study NCT01089075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets po
Study NCT03824574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Mandibular Advancement Appliance
Description: Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
Study NCT05770687 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Patients started on SGLT2 inhibitors after PCI for AMI
Study NCT00299091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz capsules 200 mg and 600 mg
Description: Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg to 320mg / day
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: 40mg to 320mg / day
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 6.25mg to 25mg / day
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: 6.25mg to 25mg / day
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg / day
Study NCT03720067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of rosuvastatin
Study NCT01049789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMB - Combination Cognitive Behavioral Therapy and Medication Management
Description: Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48.